Business
NetworkNewsWire Announces Publication Discussing Advances in Cannabinoids for use in Pain Management
New York, New York--(Newsfile Corp. - December 11, 2017) - NetworkNewsWire ("NNW"), a multif...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Discussing Advances in Cannabinoids for use in Pain ManagementNew York, New York--(Newsfile Corp. - December 11, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management,\" discusses advances in the development of cannabinoid-based topical therapies for use in alleviating pain without psychoactive side effects. To view the full publication, visit: https://www.networknewswire.com/advanced-biosynthesis-setting-new-standards-cannabinoid-based-pain-management\"Pre-clinical results in the development of the company's INM-405 candidate for the treatment of pain suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders such as temporomandibular disorders (TMD) and trigeminal neuralgia (TN) - without any observed central nervous system side effects.\"TN in particular is known for symptoms involving intense and uncontrollable face and jaw spasms, causing pain that is so severe it has been nicknamed \"the suicide disease.\" It is estimated that 12 new cases of TN occur per 100,000 persons every year, according to the National Institute of Neurological Disorders and Stroke.  Sufferers have found some relief smoking marijuana, but must do so frequently and are subject to protracted psycho-activity caused by THC. InMed recognizes the need and market opportunity for non-opioid alternatives to treat chronic and severe pain with limited side effects.\"InMed has since filed a provisional patent application for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain (http://nnw.fm/K0MRo), noting the need for therapies centered on specific non-psychoactive cannabinoids.\"About InMedInMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription d...